Literature DB >> 9058735

Epstein-Barr virus modulates 5-lipoxygenase product synthesis in human peripheral blood mononuclear cells.

J Gosselin1, P Borgeat.   

Abstract

The effect of short-term coincubations of Epstein-Barr virus (EBV) with mononuclear cells on the synthesis of leukotrienes (LT) by monocytes was investigated. Although treatment of mononuclear cells with EBV alone had no significant effect on LT synthesis by monocytes, the preincubation of mononuclear cells with EBV before the further stimulation of the cells with either the ionophore A23187, the chemoattractant formyl-Met-Leu-Phe, or the phagocytic particles zymosan strikingly enhanced the formation of both LTB4 and LTC4 above the levels of synthesis observed with the stimuli alone. Such priming effect of EBV on LT synthesis was maximal after 15 minutes of preincubation of mononuclear cells with EBV and slowly declined at longer preincubation times; the priming effect of EBV was observed both in Hank's Balanced Salt Solution and plasma. The effect of EBV was abolished by prior treatment of viral particles by heat or by antibody raised against the glycoprotein gp350 of the viral envelope, but not by UV irradiation of the viral particles. Exposure of mononuclear cells to EBV was shown to strongly enhance the activation of the 5-lipoxygenase and the release of arachidonic acid induced upon cell stimulation with a second agonist. The release of arachidonic acid by the EBV-treated mononuclear cells was inhibitable by arachidonyl trifluoromethyl ketone, an inhibitor of the 80-kD cytosolic phospholipase A2. Furthermore, EBV was shown to rapidly increase (maximum effect within 15 minutes) the levels of phosphorylated form of the cytosolic phospholipase A2 (as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis), a process related to the activation of this enzyme. These data show that the interaction of EBV with monocytes upregulates the formation of important lipid mediators of inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058735

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Infection of primary human monocytes by Epstein-Barr virus.

Authors:  M Savard; C Bélanger; M Tardif; P Gourde; L Flamand; J Gosselin
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.

Authors:  Neelam Sharma-Walia; Karthic Chandran; Kinjan Patel; Mohanan Valiya Veettil; Alexandru Marginean
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Epstein-Barr virus primes human polymorphonuclear leucocytes for the biosynthesis of leukotriene B4.

Authors:  J Gosselin; M Savard; M Tardif; L Flamand; P Borgeat
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 4.  Too much of a good thing: How modulating LTB4 actions restore host defense in homeostasis or disease.

Authors:  Stephanie L Brandt; C Henrique Serezani
Journal:  Semin Immunol       Date:  2017-10       Impact factor: 11.130

Review 5.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12

Review 6.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

Review 7.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

8.  Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection.

Authors:  Wai Mun Loke; Angelia Yee Chow; Karen Lam Mok Sing; Chung-Yung J Lee; Barry Halliwell; Erle C H Lim; Amy M L Quek; Eng Eong Ooi; Raymond C S Seet
Journal:  Virol J       Date:  2013-10-30       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.